znewcar1. Vancouver, Canada –– TheNewswire - April 7, 2022 - Teuton Resources Corp. Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan’s Key Objectives. com uses cookies on this site. About Us | Theratechnologies Inc. (THTX) stock. First Quarter Fiscal 2022 Financial Results. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. If you have HIV, it's important to know the difference. com uses cookies on this site. TH | May 19, 2023. MONTREAL, Feb. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. Senior Director, Investor Relations. Find the latest Theratechnologies Inc. T. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. For investor inquiries: Leah Gibson. MONTREAL, Oct. Theratechnologies Inc. Stockhouse. S. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We also use them to share. . . Theratechnologies (TH) has submitted a supplemental biologics license application (sBLA) to the U. , a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. Approximately US$2,000,000, or CA$2,600,000, was paid in cash at closing. S. com uses cookies on this site. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1. Further. Cookies are used to offer you a better browsing experience and to analyze our traffic. com. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. MONTREAL, Jan. Type: Company - Public (TH) Revenue: $5 to $25 million (USD) Biotech & Pharmaceuticals. Cookies are used to offer you a better browsing experience and to analyze our traffic. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Lead drug EGRIFTA (tesamorelin for injection) is being marketed for the reduction of excess abdominal fat in HIV-infected patients with. Revenues have been growing at an average rate of 10. Statut du système de négociation. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. We also use them to share usage information with our partners. (2021-01-11 | TSX:TH) Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units. MONTREAL, Sept. TH1902 is a first-in-class PDC targeting SORT1, that consists of 2 molecules of docetaxel attached to the TH19P01 peptide via a cleavable succinyl linker. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as. Focused on small-cap companies and sectors. T. 66% compared to the previous year's 69. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors Stockhouse. T. . 82 million. Browse posts by Sector and Subsector. Theratechnologies will acquire all outstanding shares of Katana for US$5,300,000 or CA$6,900,000. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. Stockhouse. 5%. MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to issue and sell up to US $50 million common shares from. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus. Montreal-based biopharmaceutical company Theratechnologies Inc. com uses cookies on this site. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. acts as investment manager. (2015-07-23 | TSX:TH) Theratechnologies Announces $9,600,000 Firm Offering of Units and Filing of Preliminary Short Form Prospectus. MONTREAL, April 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. B2Gold Declares Fourth Quarter 2023 Dividend. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 26 +15. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced preliminary efficacy data from a Phase 1 study of its lead investigational peptide-drug. - Issued and outstanding common shares to be consolidated on the basis of 1 post. . sBLA for F8 formulation of tesamorelin submitted to FDA. com. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced public offering (the “Public. Wainwright NASH Investor Conference. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies's earnings have been declining at an average annual rate of -35. com. M. S. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. : 001-35203 Mr. Stockhouse. communications@theratech. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. $30. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. com uses cookies on this site. RESSOURCES. 4 million. Cookies are used to offer you a better browsing. MONTREAL, Feb. NCU. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xToronto, Ontario-- (Newsfile Corp. Senior Director, Communications & Corporate Affairs. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. - Q3 2022 North American Revenue Growth of 19%. is an employee of TaiMed Biologics USA, Inc. TORONTO, Sept. R. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. TH | July 20, 2023. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal. Cookies are used to offer you a better browsing experience and to analyze our traffic. (2021-06-30 | TSX:TH) CORRECTION: Theratechnologies to Announce Financial Results for Its Second Quarter Fiscal 2021. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, Feb. 1M. On July 28, 2023, Theratechnologies announced that the Company had entered into an agreement with certain funds and accounts for which Marathon Asset Management, L. OTCQX – this is the premium tier of OTC stocks. TH 48% v4,15M c1. MONTREAL, Dec. $109. Stockhouse. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. However, it did not meet the equivalence limits of 0. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. 1300 (+9. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high expression of. The company was. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April 12. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development. 81 million for the quarter. 81 million for the quarter. Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021 Globe Newswire - Wed Nov 3, 2021 . MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Further information about Theratechnologies is available on the Company’s website at on SEDAR+ at and. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. Stock analysis for Theratechnologies Inc (TH:Toronto) including stock price, stock chart, company news, key statistics, fundamentals and company profile. FY2023 revenue guidance range set between $90 million and $95 million. (CSE: KOG) (" KO Gold " or the " Company ") is pleased to announce that the common shares of the Company will commence trading on the Canadian Securities Exchange (CSE) effective at the open of business on Wednesday, October 11, 2023, under the symbol " KOG ". About SORT1+ Technology™ and TH1902. - Q3 2022 Consolidated. Theratechnologies Inc. Theratechnologies (TH) provided business highlights and financial results for the second quarter and first half of fiscal year 2022; For the three- and six-month periods ending May 31, 2022, consolidated revenue was US$19,268,000 and US$37,825,000, compared to US$17,787,000 and US$33,217,000 for the same periods last year,. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. (2021-03-20 | TSX:TH) Theratechnologies Announces New Data Demonstrating Tesamorelin's Positive Effect on Immune Response Linked to Liver Inflammation. Betteryear2. com uses cookies on this site. Real-time Price Updates for Theratechnologies (TH-T), along with buy or sell indicators, analysis, charts, historical performance, news and more(2018-03-06 | TSX:TH) Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1. CA, an investment chat community for Canada's small cap marketsTheratechnologies is currently analyzing data and preparing responses to questions received from the FDA. 46. Once expert advice is considered, the Company. -4. Share your ideas and get valuable insights from the community of like minded traders and investors Headquarters. Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management. Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV. Theratechnologies Inc. We also use them to share usage information with our partners. 9 million and US. has received a $100 million binding commitment with respect to a non-dilutive term loan with an affiliate of Marathon Asset Management. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. ET. 65 per cent to C$1. . Metastasis is a form of cancer that has spread from its original site to a distant site or organ where it grows or metastasizes. 1-514-336-7800. By continuing to use our service, you agree to our use of cookies. 54% and a negative trailing twelve-month return on equity of 1,116. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. By continuing to use our service, you agree to our use of cookies. Stockhouse. com uses cookies on this site. Montréal, Québec, Canada . Stockhouse. Theratechnologies stated the primary endpoint measured a 90 per cent confidence interval of the IM injection to IV injection (0. 36 morning pop. -based clinical sites participating in the conduct of the Phase. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . 22M. Top 173 largest Canadian Companies in the Drug Manufacturers—Specialty & Generic industry by Market Cap. Theratechnologies Inc. Investor inquiries: Elif McDonald. 67% from the latest price. GUD | Complete Knight Therapeutics Inc. 8 and 1. 05M. 18% on the last trading day (Wednesday, 25th Oct 2023), rising from $1. Montréal, Québec, Canada . (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. The financial results presented in this press release are taken from the. By continuing to use our service, you agree to our use of cookies. com uses cookies on this site. Stockhouse. View Company Info for Free. This enduring webinar with Drs Arsalan Shah, Sarah Rowan, Stacey Trooskin, and Juliana Wallace will provide critical updates on specific strategies to improve testing and linkage to care, retention in care, and an overview of guidelines for treatment of HIV and HCV. By continuing to use our service, you agree to our use of cookies. MONTREAL, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Headquartered in Montreal, Theratechnologies is a biotech company that develops innovative therapies for unmet medical needs in HIV, oncology, and NASH, a type of liver disease. ET. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. com uses cookies on this site. : Renegotiated Lease to Generate Substantial Annual Savings. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of. is a speaker and consultant of Theratechnologies. 69, 1. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] Inc. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. : Nasdaq Theratechnologies Inc. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. MONTREAL, July 14, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 2015 Peel, 11th Floor Montreal, Quebec H3A 1T8 THERA technologies MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE YEAR ENDED NOVEMBER 30, 2021 The following Management’s Discussion and Analysis, or MD&A, provides Management’s point of view on the financial position and results of operations. 23) earnings per share over the last year ( ($1. Volatility Over Time: TH's weekly volatility has increased from 16% to 25% over the past year. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the strengthening of its global commercial. THERATECHNOLOGIES INC. (TH. Theratechnologies Announces Operational Update - read this article along with other careers information, tips and advice on BioSpace Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in. (2022-02-24 | TSX:TH) Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update. com. By continuing to use our service, you agree to our use of cookies. 2% for this period. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. 03, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TH) has announced preclinical findings for its peptide-drug conjugate TH1902 for the treatment of metastatic cancers. 04) earnings per share (EPS) for the quarter. 16, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We also use them to share usage information with our partners. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. Montréal, Québec, Canada . (2022-10-26 | TSX:TH) Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays. org. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ( THTX 3. 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (2020-10-22 | TSX:TH) Theratechnologies to Present at Upcoming Investor Conferences on October 29 and November 10, 2020. THTX | Complete Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. This peptide-drug conjugate (PDC) is the lead candidate stemming from Theratechnologies’ SORT1+ Technology™ in oncology. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as compared to the 2021 fiscal year. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. is a pharmaceutical company. About Theratechnologies. 8 million. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that all five of the U. Stockhouse. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. TH1902 combines Theratechnologies’ proprietary peptide to. The abstract and poster can be found on Theratechnologies’ website. Investor Relations. Trogarzo® and. Senior Director, Communications & Corporate Affairs. TORONTO, May 19, 2023 /CNW/ - This press release is being disseminated as required by. T. Watch list NEW Set a price target alert After Hours Last. Theratechnologies had a negative net margin of 36. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. (882) posted 3 minutes ago. communications@theratech. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. Q3 2023 consolidated revenue of $20. Stockhouse. This news release constitutes a “designated news release” for the purposes of the Company’s. MONTREAL, Feb. During the last trading day the stock fluctuated 12. Ibalizumab-uiyk (Trogarzo) is a medical infusion treatment for HIV infection in adults for whom other HIV medicines have not worked. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the third quarter of fiscal year 2022, ended August. About Theratechnologies. The price has fallen in 5 of the last 10 days. European Headquarters. It is the Company’s proprietary peptide linked to. By continuing to use our service, you agree to our use of cookies. com. Stockhouse. stock price gained 1. Consensus forecasts updated Jul 21. Cookies are used to offer you a better browsing experience and to analyze our traffic. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of. Montréal, Québec, Canada . 2022 Revenue Guidance Theratechnologies anticipates fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the. 9 million and US$19. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented data suggesting that tesamorelin may improve metabolic profiles in people with HIV. Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. The company’s previously announced offering was conducted by a syndicate of underwriters, including companies such as Canaccord Genuity. Cookies are used to offer you a better browsing experience and to analyze our traffic. Their average twelve-month price target is $36. We also use them to share usage information with our partners. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a commercial-stage biopharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical. MONTREAL, Oct. VANCOUVER, British Columbia, Nov. . Theratechnologies Inc. ASP | Complete Acerus Pharmaceuticals Corp. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. 06 million, an increase of. com uses cookies on this site. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650For the three- and six-month periods ended May 31, 2023, consolidated revenue was $17,549,000 and $37,457,000, compared to $19,268,000 and $37,825,000 for the same periods ended May 31, 2022. We currently market prescription products for people with HIV in the United States. FY2022 top line revenue expected to end the year at ~$80 million, in line with previously announced revenue guidance; FY2023 revenue guidance range set between $90 million and $95 million, ending the new year on a solid path to positive cash. We also use them to share usage. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Inc. High expression of the sortilin (SORT1) receptor correlates with decreased survival in triple‐negative breast cancer (TNBC) patients. “Theratechnologies’ commitment to investors at the beginning of 2023 has been to remain steadfast in delivering on key financial objectives, particularly to achieve positive adjusted EBITDA by the end of the current fiscal year,” said Philippe Dubuc, Senior Vice President and Chief Financial Officer at Theratechnologies. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. Theratechnologies Inc. stock news by MarketWatch. MONTREAL, Sept. Theratechnologies, Inc. (THTX) stock quote, history, news and other vital information to help you with your stock trading and investing. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced the publication of a preclinical study demonstrating the in vitro and in vivo efficacy of TH1902, an investigational sortilin (SORT1)-targeted peptide-drug conjugate, in inhibiting ovarian cancer and triple-negative breast cancer (TNBC. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. Microsoft to invest $500M in Quebec AI economy. 9 million as at August 31, 2023. 00. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Cookies are used to offer you a better browsing experience and to analyze our traffic. By continuing to use our service, you agree to our use of cookies. TH1902 is currently Theratechnologies’ lead investigational peptide drug conjugate candidate for the treatment of cancer derived from its SORT1+ Technology™. 5% workforce reduction. Their THTX share price targets range from $36. Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. By continuing to use our service, you agree to our use of cookies. Biopharmaceutical company Theratechnologies (TH) has closed its bought deal public offering after raising over C$58 million in proceeds. The website address for Stockhouse has changed We changed the address of the Stockhouse website from to stockhouse. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the treatment of. 40%) (As of 11/17/2023 ET) Compare Today's Range $1. When this page refreshes you will be logged in with the new address. Further.